Tsingzhi Cap
清智资本
Tsingzhi Cap (清智资本) is a venture capital fund that appears in elsewhere's corpus primarily as a co-investor in hard-tech and AI deals. It led the angel+ round in humanoid robotics startup 动易科技 in 2025, building on its earlier participation in the company's 2024 angel round alongside 峰瑞资本, Z Fund, and others . The fund also appears as a co-investor in 华深智药 (Helixon)'s 2022 Series A round in AI-powered drug discovery, alongside 5Y Capital, 高榕资本, and others . Beyond these deal mentions, elsewhere's corpus does not contain a dedicated profile of the fund's strategy, team, or AUM.
AI-generated — may contain errors, please verify.
Coverage
Embodied Intelligence, Pet Medicine, Brain Science, Gene Therapy... 6 Companies Announce New Funding Rounds | FreeS Family Funding News Vol.23
Looking forward to working alongside more outstanding founders.
Embodied AI, AI + Industry, Chips + Autonomous Driving: 5 Companies Announce Funding Rounds | FreeS Family Funding News Vol.20
Looking forward to working alongside more outstanding founders.
July: Seeking Vast Possibilities | 5Y News Monthly
The big news from last month.
5Y News | Helixon Pharma Closes Nearly 500 Million Yuan Series A to Deepen AI-Powered Drug Discovery
Building a life-science platform powered by artificial intelligence.
Helixon Closes Nearly RMB 500 Million Series A Round, AI-Powered Large-Molecule Drug Discovery
We've developed a suite of groundbreaking algorithms for protein drug design and modeling.
